Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ArriVent BioPharma (AVBP) Depreciation & Amortization (CF) (2026)

ArriVent BioPharma has reported Depreciation & Amortization (CF) over the past 1 years, most recently at -$559000.0 for Q1 2026.

  • Quarterly results put Depreciation & Amortization (CF) at -$559000.0 for Q1 2026, changed N/A from a year ago — trailing twelve months through Mar 2026 was -$559000.0 (changed N/A YoY), and the annual figure for FY2025 was -$3.0 million, changed.
  • Depreciation & Amortization (CF) reached -$559000.0 in Q1 2026 per AVBP's latest filing.
  • Across five years, Depreciation & Amortization (CF) topped out at -$559000.0 in Q1 2026 and bottomed at -$559000.0 in Q1 2026.